Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "in adults with COVID-19 disease who require oxygen or mechanical ventilation" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with a significant reduction in mortality of patients with ARDS due to COVID-19 , most probably via non-specific anti-inflammatory effects" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "with smaller reductions in LOS" provenance.
- OBJECT label "Therefore, may, in obese children" provenance.
- OBJECT label "Therefore, may, in obese children" provenance.
- OBJECT label "Therefore, may, in obese children" provenance.
- OBJECT label "Therefore, may, in obese children" provenance.
- OBJECT label "Therefore, may, in obese children" provenance.
- OBJECT label "Therefore, may, in obese children" provenance.
- OBJECT label "MD simulations" provenance.
- OBJECT label "MD simulations" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "lower severity of POST than the control group" provenance.
- OBJECT label "with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )" provenance.
- OBJECT label "with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )" provenance.
- OBJECT label "with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )" provenance.
- OBJECT label "with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )" provenance.
- OBJECT label "with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )" provenance.
- OBJECT label "with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.
- OBJECT label "in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction" provenance.